Skip to content
10-Q

Quarterly Report

Bone Biologics Corp BBLG BBLGW

0001493152-26-023163

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 1.8M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.8M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 530.62K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$804.28K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$926.13K
Stockholders Equity Q1 2026 · Mar 31, 2026 $4.67M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.38M
Stockholders Equity Q1 2026 · Mar 31, 2025 $2.91M
Stockholders Equity Q1 2026 · Dec 31, 2024 $3.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $309.39K
Current Liabilities Q1 2026 · Dec 31, 2025 $418.59K
Total Liabilities Q1 2026 · Mar 31, 2026 $309.39K
Total Liabilities Q1 2026 · Dec 31, 2025 $418.59K
Current Assets Q1 2026 · Mar 31, 2026 $4.98M
Current Assets Q1 2026 · Dec 31, 2025 $5.8M
Total Assets Q1 2026 · Mar 31, 2026 $4.98M
Total Assets Q1 2026 · Dec 31, 2025 $5.8M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.43
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$1.92
Eps Basic Q1 2026 · Mar 31, 2026 −$0.43
Eps Basic restated Q1 2026 · Mar 31, 2025 −$1.92
Sga Expense Q1 2026 · Mar 31, 2026 $663.46K
Sga Expense Q1 2026 · Mar 31, 2025 $614.91K
Rd Expense Q1 2026 · Mar 31, 2026 $141.6K
Rd Expense Q1 2026 · Mar 31, 2025 $423.58K
Net Income Q1 2026 · Mar 31, 2026 −$765.99K
Net Income Q1 2026 · Mar 31, 2025 −$1.02M
Operating Income Q1 2026 · Mar 31, 2026 −$805.05K
Operating Income Q1 2026 · Mar 31, 2025 −$1.04M